Isomorphic Labs Grabs $2.1 Billion for AI Drug Discovery
Google-backed company grabs global attention by raising funds that expand its AI Drug Discovery. In the era of Artificial Intelligence making its way into the pharma industry, this announcement sets the bar for further development in drug discovery. Isomorphic Labs, a London-based biotech company, has secured $2.1 billion in Series B funding.
The company plans to use this investment to improve its AI Drug design engine. The investment is one of the largest ever seen for the AI-focused Biotech company. This boosts the confidence that AI technology can help change the future of medicine faster than traditional methods.
A Startup Born From DeepMind
Isomorphic Labs was founded in 2021 by Demis Hassabis of Google DeepMind (backed by Alphabet Inc.). Isomorphic has committed to using cutting-edge AI technology to help shape the future of medicine by accelerating drug discovery and bringing new treatment options to market at a fraction of the cost and time required by traditional methods.
At the center of the company’s work is its AI-powered platform called the IsoDDE, short for Isomorphic Drug Design Engine. According to the company, the system uses advanced AI models that can work across different diseases and multiple drug types.
The company recently revealed that the platform has demonstrated strong predictive accuracy and can help researchers understand complex biological systems better. This could help scientists design medicines with greater precision and speed.
A Major Investment in AI-Powered Medicine
The latest round of funding was led by Thrive Capital with participation from existing investors, such as Alphabet and GV, as well as new investors MGX, CapitalG, Temasek, and the UK government’s AI fund. This recent fundraising for Isomorphic follows its first external fundraising round last October, which raised $600 million. This shows the growing demand for companies at the intersection of healthcare and artificial intelligence.
The core of Isomorphic’s strategy revolves around its AI drug discovery capabilities, which aim to transform how drugs are developed in the pharmaceutical industry. Millions of dollars and years are invested into developing each new drug through the traditional pharmaceutical development process, which typically takes over 10 years and costs billions of dollars before a new drug can be marketed. By using advanced AI and advanced computational biology, Isomorphic has the opportunity to significantly reduce the time it takes to develop a new medicine and upgrade patient care.
AlphaFold 3 and IsoDDE
The company’s AlphaFold 3 (the newest protein-structure prediction tool created with Google DeepMind’s help) has become one of the most significant tools available to researchers today. Unlike other methods for predicting protein structures, AlphaFold 3 also enables researchers to characterize protein-protein interactions and to understand how proteins interact with DNA, RNA, and small molecules. This is pivotal because the ability to predict molecular interactions is essential for building new drugs.
AlphaFold 3 is now being used as part of the more comprehensive drug discovery platform, IsoDDE. The additional funds recently raised to support the company will be used to expand IsoDDE’s scale and advance its drug pipeline through clinical trials.
Expanding Beyond Research
The company’s global expansion is supported by the newly raised funding. This expansion will facilitate opportunities for the recruitment of more experts in AI drug discovery, development, and clinical research across its divisions globally.
The company currently has its centers in London, Cambridge, Massachusetts, and Lausanne, Switzerland. Experts at Isomorphic believe that the major step in AI Drug Discovery is scaling the technology. Sir Demis Hassabis described the funding as a strong sign of confidence in the company’s AI-first approach to drug design.
Partnerships with Pharma Giants
Isomorphic Labs has earned a reputation among pharmaceutical giants worldwide. They have signed partnerships with Eli Lilly, Novartis, and Johnson & Johnson, collaborating with them to find small-molecule drugs that treat diseases whose targets remain confidential.
These partnerships focus on using AI tools to improve drug research and accelerate the discovery process. Industry experts see these collaborations as an important validation of the company’s technology and long-term potential.
The Future of AI Drug Discovery
For Alphabet, the success of Isomorphic Labs represents another example of how its AI research ecosystem is moving beyond consumer products and into industries. Alphabet president and chief investment officer Ruth Porat praised the company’s progress, saying Isomorphic has already demonstrated how AI can accelerate the pace of scientific discovery and help bring critical treatments to patients faster.
As competition intensifies in the biotech AI race, Isomorphic Labs is positioning itself as one of the leading players combining generative AI, molecular biology and large-scale computing. With AlphaFold 3 continuing to push the boundaries of biological prediction, the company’s latest funding round may mark a defining moment not just for Isomorphic itself, but for the future of AI-driven medicine as a whole.
